STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 68 filers reported holding STOKE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $161,564 | -64.0% | 41,009 | -2.8% | 0.00% | -100.0% |
| Q2 2023 | $448,320 | +155566.7% | 42,175 | +21.9% | 0.00% | – |
| Q1 2023 | $288 | -8.9% | 34,597 | +1.2% | 0.00% | – |
| Q4 2022 | $316 | -99.9% | 34,191 | +1.4% | 0.00% | -100.0% |
| Q3 2022 | $433,000 | +2.9% | 33,716 | +5.9% | 0.00% | 0.0% |
| Q2 2022 | $421,000 | +3.4% | 31,851 | +64.6% | 0.00% | 0.0% |
| Q1 2022 | $407,000 | -5.6% | 19,345 | +7.6% | 0.00% | 0.0% |
| Q4 2021 | $431,000 | -7.5% | 17,983 | -1.8% | 0.00% | 0.0% |
| Q3 2021 | $466,000 | -20.7% | 18,319 | +4.9% | 0.00% | 0.0% |
| Q2 2021 | $588,000 | -2.3% | 17,470 | +12.7% | 0.00% | 0.0% |
| Q1 2021 | $602,000 | -38.0% | 15,507 | -1.1% | 0.00% | 0.0% |
| Q4 2020 | $971,000 | +96.6% | 15,672 | +6.2% | 0.00% | 0.0% |
| Q3 2020 | $494,000 | +22.9% | 14,762 | -12.5% | 0.00% | 0.0% |
| Q2 2020 | $402,000 | -13.2% | 16,877 | -16.5% | 0.00% | 0.0% |
| Q1 2020 | $463,000 | +105.8% | 20,218 | +154.7% | 0.00% | – |
| Q4 2019 | $225,000 | – | 7,939 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |